Enhanced Screening Program
Aortic Stenosis
Echo IQ is developing the Enhanced Screening Program for Aortic Stenosis (ESP-AS) in order to bring treatment closer to patients.
ESP-AS is being developed as a tool for clinicians and physicians to support earlier identification of mortality-risk in patients who might benefit from intervention or more proactive vigilance.
This proprietary digital (cloud-based) solution will generate a risk assessment for aortic stenosis using echocardiographic measurement data from a standard cardiothoracic ultrasound. ESP will analyse this data to generate a risk indicator. This will be augmented by an additional check for Severe AS as defined by the current AHA guidelines.
Analyses 15x more
variables than
standard echo
<2 sec
per result
200 million cardiac data points used to develop proprietary algorithm
Supports
enhanced
diagnosis
Earlier risk detection
ESP-AS is being designed to identify patients having the at-risk phenotype for aortic stenosis, in many cases before they present with all of the current guideline diagnostic thresholds.
Improved diagnosis
Eliminate subjectivity in your echo analysis, and the number of missed opportunities and inconsistencies. Fast and accurate.
Trusted data
Validated against the worlds largest echocardiographic database linked to mortality. If you would like a peer-to-peer discussion with our CMO, please connect with our Cardiologist.
Accuracy in
risk-prediction
Reassurance knowing that human intelligence is supplemented by AI-driven technology backed by hundreds of millions of cardiac datapoints.
Reassurance
Al algorithms that have been validated against clinical guidelines and are showing model accuracy in excess
of 98%.
Peace of mind
Peace of mind that all variables have been considered in order to deliver optimal care.
Improved patient outcomes
ESP-AS is being developed to support improved accuracy and consistency in diagnosis, enabling health systems to provide better care to more patients.
More opportunities
to treat
Identify more patients who might benefit from treatment. Reduce the number of missed opportunities, and inconsistencies in evaluation.
Trusted data
Validated against the world’s largest echocardiographic database that includes mortality outcomes.
Enhanced Screening Program
Heart Failure
DUE 2023
Echo IQ has commenced development of a new module for its Enhanced Screening Program. ESP for Heart Failure (ESP-HF) is anticipated to complement the ESP-AS solution, to increase detection of risk for structural heart disease more broadly.
ESP-HF is being developed as a tool for clinicians and physicians to support earlier identification of mortality-risk in patients who might benefit from intervention or more proactive vigilance.
This proprietary digital (cloudbased) solution will generate a risk assessment for systolic and diastolic heart failure using echocardiographic measurement data from a standard transthoracic ultrasound.
Enhanced Screening Program
Mitral Regurgitation
DUE 2023
Echo IQ has commenced development of a new module for its Enhanced Screening Program. ESP for Mitral Regurgitation (ESP-MR) is anticipated to complement the ESP-AS and ESP-HF solutions, to increase detection of risk for structural heart disease more broadly.
ESP-MR is being developed as a tool for clinicians and physicians to support earlier identification of mortality-risk in patients who might benefit from intervention or more proactive vigilance.
This proprietary digital (cloud-based) solution will generate a risk assessment for mitral regurgitation using echocardiographic measurement data from a standard transthoracic ultrasound.
Suite 404, 309 George Street, Sydney NSW 2000
ABN 48 142 901 353
All rights reserved. Copyright © Echo IQ 2021.
Suite 404, 309 George Street
Sydney NSW 2000
ABN 48 142 901 353
All rights reserved. Copyright © Echo IQ 2021.
